Clinical Trial Update: Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update aiming to establish the recommended biological dose for AE37 peptide vaccine with pembrolizumab in advanced triple-negative breast cancer t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AE37 peptide vaccine (AE37 peptide vaccine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NuGenerex Immuno-Oncology | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN